Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Helios and Matheson Analytics Inc May Win With MoviePass

By Chris Lau, InvestorPlace Contributor

Something should not sit right with investors when a company hints at blockchain technology getting incorporated into its business model. But when Helios and Matheson…

Valeant Pharmaceuticals Intl Inc Stock Rides High as More Good News Awaits

By Chris Lau, InvestorPlace Contributor

VRX stock has soared in recent months as investors expect Valeant to continue improving its business in 2018.

Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally

By Chris Lau, InvestorPlace Contributor

Marijuana stock investing is fraught with risks, after the big run-up recently. Scrutinize the earnings potential for these companies first.

Bet Against Synergy Pharmaceuticals Inc Stock Has Paid off — for Now

By Chris Lau, InvestorPlace Contributor

SGYP stock's under-performance is due to Trulance sales not ramping up fast enough and that could change in the very near future.

Facebook, Inc. Still Pledging to Become a Better Social Destination

By Chris Lau, InvestorPlace Contributor

Facebook stock is hovering at new highs and more growth is on the way as management re-invents the site to better serve its users.

Load More